27 / 30
Blood collection,
plasma isolation &
cfDNA extraction
•
All base substitutions with ≥0.5%
allele frequency
•
Remove germline polymorphisms &
predicted driver mutations
bTMB
Sequencing
POPLAR
(training)
OAK
(validation)
Gandara, DR et al. ESMO 2017
Plasma samples from the Phase II POPLAR
(n=298) study and the Phase III OAK (n=583)
study
retrospectively tested for bTMB, using
394 gene-based NGS assay
Tumor Mutational Burden in
plasma and Atezolizumab efficacy
in 2L+ NSCLC
Increasing Atezolizumab benefit with higher bTMB cut-points
Progression-Free Survival – OAK